Investigating the structure and function of a key protein in HCMV
Structure, antigenicity, and function of HCMV fusogen gB
['FUNDING_R01'] · TUFTS UNIVERSITY BOSTON · NIH-11116915
This study is looking at a part of the human cytomegalovirus that helps it infect cells, to better understand how our immune system responds to it, which could help create better vaccines to protect people, especially those who are more at risk.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TUFTS UNIVERSITY BOSTON (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11116915 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the human cytomegalovirus (HCMV) glycoprotein B (gB), which plays a crucial role in the virus's ability to infect cells. The researchers aim to characterize the structure and immune response related to gB, particularly its prefusion form, which is essential for developing effective vaccines. By using advanced techniques like cryo-electron microscopy, they will explore how gB interacts with antibodies and contributes to viral entry. This knowledge could lead to improved strategies for preventing HCMV infections, especially in vulnerable populations.
Who could benefit from this research
Good fit: Ideal candidates for this research are immunocompromised individuals, such as organ transplant recipients, and pregnant women at risk of HCMV transmission.
Not a fit: Patients who are not immunocompromised and have no risk factors for HCMV infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines against HCMV, reducing the risk of severe disease in immunocompromised patients and preventing transmission from mothers to their infants.
How similar studies have performed: Previous research has shown promise in understanding viral proteins for vaccine development, indicating that this approach could yield significant advancements.
Where this research is happening
BOSTON, UNITED STATES
- TUFTS UNIVERSITY BOSTON — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HELDWEIN, EKATERINA — TUFTS UNIVERSITY BOSTON
- Study coordinator: HELDWEIN, EKATERINA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.